Veeva Systems: Wells Fargo Maintains Overweight, Raises PT to $341 from $326.
ByAinvest
Thursday, Aug 28, 2025 10:51 am ET1min read
VEEV--
Veeva Systems provides cloud-based software solutions for the life sciences industry, including Veeva Commercial Cloud, Veeva Vault PromoMats, Veeva Vault Medical, Veeva Crossix, Veeva OpenData, Veeva Link, and Veeva Compass. The company has seen solid revenue growth of 14.8% over the last twelve months, with a "GREAT" Financial Health score according to InvestingPro data [2].
The price target increase follows several recent developments. Veeva Systems has settled its ongoing litigation with IQVIA, ending disputes that began in 2017. The settlement includes mutual data access agreements, allowing both companies to provide enhanced products and services to their customers [2]. Additionally, Boehringer Ingelheim has adopted Veeva’s OpenData and Network solutions across more than 100 countries, aiming to improve customer data accuracy and support artificial intelligence capabilities. Furthermore, Veeva Systems secured a new commitment from Merck, becoming the sixth top 20 global pharmaceutical company to transition to Veeva’s Vault platform [2].
Despite these positive developments, short interest in Veeva has more than doubled since the beginning of the year to approximately 4.6 million shares, reaching its highest level since 2019. This represents less than 3% of the company’s float and has decreased from its June peak of 5.3 million shares [2].
Veeva Systems reported earnings of $1.97 per share for the quarter, topping the consensus estimate of $1.74 by $0.23. The company had revenue of $759.04 million during the quarter, compared to analysts' expectations of $728.38 million. The company's net margin was 27.34% and return on equity was 13.96% [1].
Institutional investors own 88.20% of the company's stock, with several recent increases in holdings. Tower Research Capital LLC, Integrated Wealth Concepts LLC, Kovitz Investment Group Partners LLC, Capital Analysts LLC, and Johnson Financial Group Inc. all increased their positions in the fourth quarter [1].
References:
[1] https://www.marketbeat.com/instant-alerts/veeva-systems-nyseveev-price-target-raised-to-32600-at-wells-fargo-company-2025-08-26/
[2] https://www.investing.com/news/analyst-ratings/veeva-systems-stock-price-target-raised-to-326-by-wells-fargo-93CH-4210533
WFC--
Veeva Systems: Wells Fargo Maintains Overweight, Raises PT to $341 from $326.
Wells Fargo & Company has raised its price target for Veeva Systems (NYSE: VEEV) from $326.00 to $341.00, indicating a potential upside of 14.17% from the stock's previous close. The brokerage maintains an "overweight" rating on the technology company's stock. This adjustment reflects a valuation shift to fiscal year 2027 estimates and comes at a time when investor sentiment toward Veeva appears cautious despite the stock's 38% year-to-date gain compared to the S&P 500’s 9% increase [2].Veeva Systems provides cloud-based software solutions for the life sciences industry, including Veeva Commercial Cloud, Veeva Vault PromoMats, Veeva Vault Medical, Veeva Crossix, Veeva OpenData, Veeva Link, and Veeva Compass. The company has seen solid revenue growth of 14.8% over the last twelve months, with a "GREAT" Financial Health score according to InvestingPro data [2].
The price target increase follows several recent developments. Veeva Systems has settled its ongoing litigation with IQVIA, ending disputes that began in 2017. The settlement includes mutual data access agreements, allowing both companies to provide enhanced products and services to their customers [2]. Additionally, Boehringer Ingelheim has adopted Veeva’s OpenData and Network solutions across more than 100 countries, aiming to improve customer data accuracy and support artificial intelligence capabilities. Furthermore, Veeva Systems secured a new commitment from Merck, becoming the sixth top 20 global pharmaceutical company to transition to Veeva’s Vault platform [2].
Despite these positive developments, short interest in Veeva has more than doubled since the beginning of the year to approximately 4.6 million shares, reaching its highest level since 2019. This represents less than 3% of the company’s float and has decreased from its June peak of 5.3 million shares [2].
Veeva Systems reported earnings of $1.97 per share for the quarter, topping the consensus estimate of $1.74 by $0.23. The company had revenue of $759.04 million during the quarter, compared to analysts' expectations of $728.38 million. The company's net margin was 27.34% and return on equity was 13.96% [1].
Institutional investors own 88.20% of the company's stock, with several recent increases in holdings. Tower Research Capital LLC, Integrated Wealth Concepts LLC, Kovitz Investment Group Partners LLC, Capital Analysts LLC, and Johnson Financial Group Inc. all increased their positions in the fourth quarter [1].
References:
[1] https://www.marketbeat.com/instant-alerts/veeva-systems-nyseveev-price-target-raised-to-32600-at-wells-fargo-company-2025-08-26/
[2] https://www.investing.com/news/analyst-ratings/veeva-systems-stock-price-target-raised-to-326-by-wells-fargo-93CH-4210533

Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue

Comments
No comments yet